Crenae Therapeutics is focused on the development of anti-ASPH therapeutics for the treatment of metastatic cancer. ASPH inhibitors are non-toxic, orally bioavailable, Notch pathway modulators without dose limiting GI toxicity like previous Notch therapeutics. A robust IP portfolio, including small molecules, antibody diagnostics and therapeutics, and backup chemotypes provides a strong IP foundation for developing anti-ASPH therapeutics. Target cancers include veterinary, human orphan cancers such as cholangiocarcinoma and fibrolamellar hepatocellular carcinoma, and large market cancers including lung, hepatocellular carcinoma, breast, pancreatic, gastric and colon cancers.